researc-dev

Tutkimus ja tuotekehitys

Sanofi Pasteur MSD on ylpeä voidessaan yhdistää maailman kahden johtavan rokoteyrityksen kehitystyön rokotteiden kehittämisessä ja toimittamisessa.

  • SPMSD pipeline

    R&D Key developments Registration New Vaccines
     

    Dengue fever vaccine

    Pneumoconjugate vaccine

    Cervical cancer & other HPV-related diseases 9-type HPV vaccine

     

    Hexyon

    DTP-HepB-Polio-Hib vaccine

    Zostavax

    Shingles and Postherpetic Neuralgia

    Sanofi Pasteur pipeline

    Merck & Co. pipeline

    Joint SP/Merck development

  • Sanofi Pasteur R&D Portfolio

    R&D Key developments Registration New Vaccines

    Tuberculosis

    Recombinant subunit vaccine

    Rotavirus

    Live attenuated tetravalent oral vaccine

    Streptococcus pneumonia

    Meningitis & pneumonia vaccine

    Pseudomonas aeruginosa

    Antibody fragment product. Prevention of ventilator-associated pneumonia

    Meninge ACYW conj.

    2nd generation, meningitis in infants

    Rabies VRVg

    Purified vero rabies vaccine

    Rabies

    mAb post exposure prophylaxis

    ACAM-Cdiff

    Clostridium difficile taxoid vaccine

    Quadracel

    Diphteria, tetanus & pertussis polio 4-6 years of age

    Fluzone QIV

    Quadrivalent inactivated flu vaccine

    Pediatric hexavalent vaccine

    DTP-HepB-Polio-Hib vaccine

    Dengue

    Mid-to-severe dengue fever vaccine

    Hexacima/Hexacim

    DTP-HepB-Polio-Hib vaccine

  • Merck R&D Portfolio

    Phase 2 Phase 3 Registration

    Pneumoconjugate vaccine

    v114

    Cervical cancer & other HPV-related diseases 9-type HPV vaccine

    V503

    Pediatric hexavalent vaccine DTP-HepB-Polio-Hib

    V419

    Shingles (Herpes Zoster)

    Inactive VZV vaccine V212

     
  • SPMSD pipeline      
  • Sanofi Pasteur R&D Portfolio
  • Merck R&D Portfolio